Inhibition of sialidase activity as a therapeutic approach
Open accessThe DOI matches its Crossref record; 47 of the 48 references it cites were found in a registry or an index.
Abstract
The demand for novel anti-influenza drugs persists, which is highlighted by the recent pandemics of influenza affecting thousands of people across the globe. One of the approaches to block the virus spreading is inhibiting viral sialidase (neuraminidase). This enzyme cleaves the sialic acid link between the newly formed virions and the host cell surface liberating the virions from the cell and maintaining the cycle of infection. Viral neuraminidases appear therefore as attractive therapeutic targets for preventing further spread of influenza infection. Compared to ion channel blockers that were the first approved anti-influenza drugs, neuraminidase inhibitors are well tolerated and target both influenza A and B viruses. Moreover, neuraminidase/sialidase inhibitors may be useful for managing some other human pathologies, such as cancer. In this review, we discuss the available knowledge on neuraminidase or sialidase inhibitors, their design, clinical application, and the current challenges.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rational design of potent sialidase-based inhibitors of influenza virus replication
von Itzstein, M., Wu, W.-Y., Kok, G. B., Pegg, M. S., Dyason, J. C., Jin, B., Van Phan, T., Smythe, M. L., White, H. F., Oliver, S. W., et al. (1993) · Nature · doi:10.1038/363418a0 · Cited by 1,862 · cited 2×
“Neuraminidase inhibitors are not free from side effects, such as nausea, vomiting, dizziness, sinusitis, runny or stuffy nose, cough, diarrhea, and headache.(5) The interpretation of results of culture-based antiviral assays is complicated by several factors specific to neuraminidase inhibitors: 1.”
BackgroundInfluenza neuraminidase inhibitors: antiviral action and mechanisms of resistance
McKimm‐Breschkin, J. L. (2013) · Influenza and Other Respiratory Viruses · doi:10.1111/irv.12047 · Cited by 390
Mammalian sialidases: Physiological and pathological roles in cellular functions
Miyagi, T., & Yamaguchi, K. (2012) · Glycobiology · doi:10.1093/glycob/cws057 · Cited by 382
Hurt, A. C., Besselaar, T. G., Daniels, R. S., Ermetal, B., Fry, A., Gubareva, L., Huang, W., Lackenby, A., Lee, R. T. C., Lo, J., et al. (2016) · Antiviral Research · doi:10.1016/j.antiviral.2016.06.001 · Cited by 270
Involvement of a Non-Human Sialic Acid in Human Cancer
Samraj, A. N., Läubli, H., Varki, N., & Varki, A. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00033 · Cited by 196
Systematic review of influenza resistance to the neuraminidase inhibitors
Thorlund, K., Awad, T., Boivin, G., & Thabane, L. (2011) · BMC Infectious Diseases · doi:10.1186/1471-2334-11-134 · Cited by 189
Serum sialylation changes in cancer
Zhang, Z., Wuhrer, M., & Holst, S. (2018) · Glycoconjugate Journal · doi:10.1007/s10719-018-9820-0 · Cited by 177
Influenza neuraminidase: A druggable target for natural products
Grienke, U., Schmidtke, M., von Grafenstein, S., Kirchmair, J., Liedl, K. R., & Rollinger, J. M. (2012) · Nat. Prod. Rep. · doi:10.1039/c1np00053e · Cited by 158
Neuraminidase inhibitors for influenza B virus infection: Efficacy and resistance
Burnham, A. J., Baranovich, T., & Govorkova, E. A. (2013) · Antiviral Research · doi:10.1016/j.antiviral.2013.08.023 · Cited by 141
Lackenby, A., Besselaar, T. G., Daniels, R. S., Fry, A. M., Gregory, V., Gubareva, L. V., Huang, W., Hurt, A. C., Leang, S.-K., Lee, R. T. C., et al. (2018) · Antiviral Research · doi:10.1016/j.antiviral.2018.07.001 · Cited by 139
Cited by
Antiviral Properties of Flavonoids and Delivery Strategies
Ninfali, P., Antonelli, A., Magnani, M., & Scarpa, E. S. (2020) · Nutrients · doi:10.3390/nu12092534 · Cited by 205
Sialic acid metabolism as a potential therapeutic target of atherosclerosis
Zhang, C., Chen, J., Liu, Y., & Xu, D. (2019) · Lipids in Health and Disease · doi:10.1186/s12944-019-1113-5 · Cited by 91
Sialic Acids as Receptors for Pathogens
Burzyńska, P., Sobala, L. F., Mikolajczyk, K. P., Jodłowska, M., & Jaśkiewicz, E. (2021) · Biomolecules · doi:10.3390/biom11060831 · Cited by 71
The functional roles of protein glycosylation in human maternal–fetal crosstalk
Zhong, J., Li, J., Burton, G. J., Koistinen, H. K., Cheung, K. W., Ng, E. H. Y., Yao, Y., Yeung, W. S. B., Lee, C., & Chiu, P. C. N. (2023) · Human Reproduction Update · doi:10.1093/humupd/dmad024 · Cited by 50
Recent progress in chemical approaches for the development of novel neuraminidase inhibitors
Mahal, A., Duan, M., Zinad, D. S., Mohapatra, R. K., Obaidullah, A. J., Wei, X., Pradhan, M. K., Das, D., Kandi, V., Zinad, H. S., et al. (2021) · RSC Advances · doi:10.1039/d0ra07283d · Cited by 46
Metadata
- Authors
- Glanz, V. Y., Myasoedova, V. A., Grechko, A. V., & Orekhov, A. N.
- Affiliations
- Voronezh State University (RU)
- Research Institute of General Pathology and Pathophysiology, the Russian Academy of Medical Sciences (RU)
- V.A. Negovsky Scientific Research Institute of General Reanimatology (RU)
- Corresponding author
- Orekhov, Alexander N
- Venue
- Drug Design Development and Therapy
- Publisher
- Informa UK Limited
- Published
- 2018-10
- Volume
- Volume 12
- Pages
- 3431-3437
- ISSN
- 1177-8881 (ISSN-L)
- PMC
- PMC6186905
- OpenAlex
- W2896331548
- Cited by
- 59
- References
- 48
- Citations by year
- 2026: 1 · 2025: 12 · 2024: 11 · 2023: 4 · 2022: 6 · 2021: 8 · 2020: 12 · 2019: 4 · 2018: 1
- FWCI
- 0.89
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Drug Design Development and Therapy (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
- Funders
- Russian Science Foundation (18-15-00254)
- Topics
- Health Sciences › Medicine › Epidemiology › Influenza Virus Research Studies
- Physical Sciences › Chemistry › Organic Chemistry › Carbohydrate Chemistry and Synthesis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Glycosylation and Glycoproteins Research
- Keywords
- neuraminidase inhibitors, sialidase inhibitors, influenza virus, anti-influenza drugs, sialic acid, viral shedding, influenza A and B, drug design, cancer therapy, clinical application
- MeSH terms
- Animals, Antiviral Agents, Enzyme Inhibitors, Humans, Influenza, Human, Neuraminidase, Influenza A virus, Influenza B virus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Inhibition of sialidase activity as a therapeutic approach. https://app.cochat.ai/papers/10.2147/dddt.s176220
- The paper
- Glanz, V. Y., Myasoedova, V. A., Grechko, A. V., & Orekhov, A. N. (2018). Inhibition of sialidase activity as a therapeutic approach. Drug Design Development and Therapy. https://doi.org/10.2147/dddt.s176220
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.